Black Belt TX forms a strategic partnership with Praxis Biotech to develop new therapies targeting stress response pathways in cancer.
Stevenage, UK and San Francisco, US – 5 November 2019. Black Belt TX, a company focused on targeting stress response pathways in cancer, and Praxis Biotech, a biotech company focused on the discovery of small molecules modulating cellular stress mechanisms in different disease areas, have entered into a strategic partnership to jointly discover and develop new first-in-class small molecule therapeutics to undisclosed targets which are aimed at modulating key…
CAMBRIDGE, UK, NEW YORK, HOUSTON and SOUTH SAN FRANCISCO, 06 November, 2019 — Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma.
Under the agreement, Artios has exclusive rights to research, develop, manufacture and commercialize products globally. The lead candidate is expected to be ready for Investigational New Drug (IND) application by the second half of 2020.
“…
A new report released today by BioBeat entitled “50 Movers & Shakers in BioBusiness 2019” includes five women from organisations based at Stevenage Bioscience Catalyst (SBC) as well as two Board members. The report highlights the top female talent in the pharma and biotech sectors within the UK.
The report focuses on the impact of individuals in five key areas, namely science, finance, collaboration, patient impact and infrastructure. The SBC-based individuals which spanned the segments are:
• Sally Ann Forsyth, CEO, Stevenage Bioscience Catalyst
• Veronique Bouchet, Chief Medical Officer…
Cambridge, UK, 05 November: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to welcome Steven S. Martin to its board.
Mr Martin is managing partner of Paxton Advisors, LLC a business advisory and consulting firm based in Omaha, Nebraska. Previously, Mr Martin was President and Chief Executive Officer for Blue Cross and Blue Shield of Nebraska (BCBSNE), leading the company’s executive management team for over 16 years and serving as a member of the board of directors from…
Cambridge, UK, 04 November 2019: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and Sentinel Oncology, today announce an expansion of their collaboration to accelerate the progression of SOL686, a novel allosteric Polo-like kinase 1 (PLK1) inhibitor through preclinical development and IND enabling studies for the treatment of Glioma.
Mitotic PLKs are widely recognised as playing crucial roles in disease causing pathways, including K-Ras mutant cancers. Traditional approaches to drugging PLK enzymes have focused on targeting their…
Arecor strengthens management team to accelerate partnership opportunities.
Arecor Limited , the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Jim MacDonald-Clink as Vice President, Business Development with immediate effect.
Jim, who joins the Arecor Leadership team from Mundipharma, will be responsible for extending and expanding areas of growth. At Mundipharma, Jim was responsible for Business Development and established the biosimilar platform and oncology strategy via acquisition and licensing agreements. His…
AMSBIO has introduced human recombinant iMatrix Laminin 211 fragment for the purification and maintenance of cardiomyocytes in culture.The Laminin family of glycoproteins are an integral part of the structural scaffolding in almost every tissue of an organism. They are secreted and incorporated into cell-associated extracellular matrices. Laminin is vital for the maintenance and survival of tissues. Defective Laminins can cause muscles to form improperly, leading to a form of muscular dystrophy, lethal skin blistering disease and defects of the kidney filter.Laminin 211 is known to…
Just as when you sell a house you need all your ducks in a row when you hit the market, so too is preparation equally crucial for a tech start up seeking funding. Anyone looking to grow their business should attend the workshop, which will be delivered by Simon Portman, a Solicitor at Marks & Clerk. The workshop will cover:
• Good housekeeping and risk management.
• Team dynamics
• Contracts and legal matters
• Intellectual property strategy
• Pitfalls to avoid
When: Thursday 21st November
Time: This will depend on level of interest
• 5-7 delegates: 15.00 -17.30 in the meeting room
• 8+…
CAMBRIDGE, UK, 30 October 2019 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has moved to Coldham’s Business Park, Cambridge, UK. The new facility will enable the continued growth of the Company as it continues in its mission to develop a desktop DNA synthesis platform based on its proprietary silicon chip.
Evonetix, previously based at Chesterford Research Park, now occupies 15,000 square feet at Coldham’s Business Park, comprising 8,000 square feet of fully fitted and equipped…